In another Phase II study, the addition of the PD-L1 inhibitor durvalumab to standard therapy moderately prolonged survival in patients with newly diagnosed MGMT-unmethylated glioblastoma compared with historical controls: 15.1 vs. 12.7 months, respectively [22]. The gene discussed is MGMT; the disease is glioblastoma.